by Clinical Neuropsychologist | Wednesday, August 21, 2024 | Dementia
Abstract INTRODUCTION CT1812 is in clinical development for the treatment of Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) exploratory proteomics was employed to identify pharmacodynamic biomarkers of CT1812 in mild to moderate AD from two independent...
by Clinical Neuropsychologist | Wednesday, August 21, 2024 | Dementia
Abstract Neurogenesis persists throughout adulthood in the hippocampus and contributes to specific cognitive functions. In Alzheimer’s disease (AD), the hippocampus is affected by pathology and functional impairment early in the disease. Human AD patients have...
by Clinical Neuropsychologist | Wednesday, August 21, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Sarah Walter, Rochelle Long, Cynthia Huling Hummel | August 21,...
by Clinical Neuropsychologist | Saturday, August 17, 2024 | Dementia
Dementia, Volume 23, Issue 7, Page 1172-1182, October 2024. Future populations of older adults in the UK, those aged 65+, will demonstrate increased diversity in terms of their ethnic identity resultant from the ageing of the post-war migrants from India, Pakistan,...
by Clinical Neuropsychologist | Friday, August 16, 2024 | Dementia
Abstract INTRODUCTION Geographic variation in diagnosed cases of Alzheimer’s disease and related dementias (ADRD) could be due to underlying population risk or differences in intensity of new case identification. Areas with low ADRD diagnostic intensity could be...